+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma

Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia 16(11): 610-615

To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058635211

Download citation: RISBibTeXText

PMID: 27618360

DOI: 10.1016/j.clml.2016.08.007

Related references

The clinical significance of cereblon expression in multiple myeloma. Leukemia Research 38(1): 23-28, 2014

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma. International Journal of Molecular Sciences 18(9):, 2017

Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?. European Journal of Haematology 92(1): 13-18, 2014

Prognostic significance of NY-ESO-1 gene expression in multiple myeloma patients. Blood 102(11): 368b, 2003

Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma. Journal of Translational Medicine 16(1): 363, 2018

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121(4): 624-627, 2013

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. British Journal of Haematology 161(5): 695-700, 2013

Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Medical Oncology 25(4): 451-457, 2008

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of Hematology 93(8): 1371-1380, 2014

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leukemia and Lymphoma 60(2): 462-470, 2019

Cereblon expression in multiple myeloma: not ready for prime time. British Journal of Haematology 163(2): 282-284, 2013

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leukemia Research 44: 32-39, 2016

Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226. Genetics and Molecular Research 14(4): 13588-13594, 2015

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica 103(8): E368, 2018

The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in Multiple Myeloma and its Prognostic Significance. Medical Science Monitor 24: 6340-6348, 2018